These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36079085)

  • 1. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS).
    Hughes DA; Deegan P; Giraldo P; Göker-Alpan Ö; Lau H; Lukina E; Revel-Vilk S; Scarpa M; Botha J; Gadir N; Zimran A;
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36079085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat.
    Sidhu K; Boyd SK; Khan A
    Mol Genet Metab Rep; 2020 Sep; 24():100606. PubMed ID: 32509532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease.
    Kleytman N; Ruan J; Ruan A; Zhang B; Murugesan V; Lin H; Guo L; Klinger K; Mistry PK
    Mol Genet Metab Rep; 2021 Dec; 29():100798. PubMed ID: 34485083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey.
    Schwartz IVD; Göker-Alpan Ö; Kishnani PS; Zimran A; Renault L; Panahloo Z; Deegan P;
    Mol Genet Metab Rep; 2018 Mar; 14():73-79. PubMed ID: 29326879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy.
    Istaiti M; Becker-Cohen M; Dinur T; Revel-Vilk S; Zimran A
    J Clin Med; 2022 Oct; 11(21):. PubMed ID: 36362492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Treatment of Gaucher Disease with Velaglucerase Alfa in ERT-Naïve Patients from the Gaucher Outcome Survey (GOS) Registry.
    Deegan P; Lau H; Elstein D; Fernandez-Sasso D; Giraldo P; Hughes D; Zimran A; Istaiti M; Gadir N; Botha J; Revel-Vilk S;
    J Clin Med; 2024 May; 13(10):. PubMed ID: 38792324
    [No Abstract]   [Full Text] [Related]  

  • 7. High-Dose Ambroxol Therapy in Type 1 Gaucher Disease Focusing on Patients with Poor Response to Enzyme Replacement Therapy or Substrate Reduction Therapy.
    Istaiti M; Frydman D; Dinur T; Szer J; Revel-Vilk S; Zimran A
    Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteonecrosis in Gaucher disease in the era of multiple therapies: Biomarker set for risk stratification from a tertiary referral center.
    Basiri M; Ghaffari ME; Ruan J; Murugesan V; Kleytman N; Belinsky G; Akhavan A; Lischuk A; Guo L; Klinger K; Mistry PK
    Elife; 2023 May; 12():. PubMed ID: 37249220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients.
    Malinová V; Poupětová H; Řeboun M; Dvořáková L; Reichmannová S; Švandová I; Murgašová L; Kasper DC; Magner M
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat.
    Mikosch P; Reed M; Baker R; Holloway B; Berger L; Mehta AB; Hughes DA
    Calcif Tissue Int; 2008 Jul; 83(1):43-54. PubMed ID: 18553043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3.
    Lee NC; Chien YH; Wang CH; Wong SL; Peng SS; Tsai FJ; Hwu WL
    Mol Genet Metab Rep; 2022 Jun; 31():100867. PubMed ID: 35782609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.
    Marshall J; McEachern KA; Chuang WL; Hutto E; Siegel CS; Shayman JA; Grabowski GA; Scheule RK; Copeland DP; Cheng SH
    J Inherit Metab Dis; 2010 Jun; 33(3):281-9. PubMed ID: 20336375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gaucher disease and its treatment options.
    Bennett LL; Mohan D
    Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry.
    Elstein D; Belmatoug N; Bembi B; Deegan P; Fernandez-Sasso D; Giraldo P; Göker-Alpan Ö; Hughes D; Lau H; Lukina E; Revel-Vilk S; Schwartz IVD; Istaiti M; Botha J; Gadir N; Schenk J; Zimran A;
    J Clin Med; 2024 Jun; 13(12):. PubMed ID: 38930117
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
    J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.
    Wyatt K; Henley W; Anderson L; Anderson R; Nikolaou V; Stein K; Klinger L; Hughes D; Waldek S; Lachmann R; Mehta A; Vellodi A; Logan S
    Health Technol Assess; 2012; 16(39):1-543. PubMed ID: 23089251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histologic and ultrastructural study of intracranial Gaucheroma causing deafness in a patient with Gaucher disease type 3: Effects of substrate reduction therapy.
    Yano S; McGowan R; Warren M
    Mol Genet Metab Rep; 2024 Sep; 40():101106. PubMed ID: 38974840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very rare condition of multiple Gaucheroma: A case report and review of the literature.
    Tseng SY; Niu DM; Chu TH; Yeh YC; Huang MH; Yang TF; Liao HC; Chiang CC; Ho HC; Soong WJ; Yang CF
    Mol Genet Metab Rep; 2019 Sep; 20():100489. PubMed ID: 31341788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attitudes of Individuals with Gaucher Disease toward Substrate Reduction Therapies.
    Wagner VF; Northrup H; Hashmi SS; Nguyen JM; Koenig MK; Davis JM
    J Genet Couns; 2018 Feb; 27(1):169-176. PubMed ID: 28803392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary Involvement Responsive to Enzyme Replacement Therapy in an Elderly Patient with Gaucher Disease.
    Vellas D; Gramont B; Grange R; Cathébras P
    Eur J Case Rep Intern Med; 2021; 8(9):002802. PubMed ID: 34671576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.